Reports Q1 revenue $696.6M, consensus $617.07M. The company said, “We had an outstanding first quarter, reaching over one million units processed in a single quarter for the first time and delivering strong growth across all areas. We are seeing the impact of strong 2025 data readouts and innovation translating into increased adoption, particularly for Signatera (NTRA) and Fetal Focus, reinforcing our confidence in the long-term opportunity to transform patient care.”
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera announces evidence for Prospera test at 2026 ISHLT
- Spotify, Sandisk, Natera, Biogen, Tesla Trending With Analysts
- Natera initiated with an Outperform at William Blair
- Natera: Premium-Valued Leader in MRD Positioned for Long-Term Growth and Margin Expansion
- Natera highlights Allogene Therapeutics’ analysis from ALPHA3 trial